Drug recall · October 7, 2020
Buprenorphine Transdermal System 5 mcg/hour recall
Why: Failed Stability Specifications: Below specification result for buprenorphine release rate.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only, Manufactured by: 3M Drug Delivery Systems, 19901 Nordhoff street, Northridge, CA 91324 USA, Manufactured for: Teva Pharmaceuticals USA Inc., North Wales, PA 19454, carton NDC: 0093-3656-40, patch NDC: 0093-3656-21.
- Lots / codes
Lot # 190017, exp. 02/2021; 190161, exp. 08/2021
- Quantity
- 32,543 cartons
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Nationwide in the U.S. and PR
- Initiated
- September 4, 2020 · Voluntary: Firm initiated
- Classified
- October 1, 2020
- Reported
- October 7, 2020
- Ended
- August 26, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.